About durvaluma b
PD-L1 immune checkpoint inhibitor
Used for
- Non-small cell lung cancer
- Small cell lung cancer
- Biliary tract cancer
- Liver cancer
Usual adult dose
Often 1,500 mg by IV infusion every 3 or 4 weeks; dose and schedule depend on cancer and other medicines.
Common side effects
- Tiredness
- Cough or shortness of breath
- Rash or itching
- Diarrhea
Important warnings
- Immune reactions can inflame the lungs, bowel, liver, kidneys, or hormone glands.
- Seek urgent care for severe breathing problems, persistent diarrhea, or yellowing skin.
- Infusion reactions can occur during or shortly after treatment.
- Tell clinicians about autoimmune disease or organ transplant; treatment may worsen these risks.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least 3 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least 3 months after the last dose.
Interactions
- No major direct drug interactions are established; disclose all medicines and supplements.
- Other immune-activating medicines may increase immune-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.